StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a report published on Thursday morning. The brokerage issued a sell rating on the medical research company’s stock.
OpGen Price Performance
NASDAQ:OPGN opened at $1.90 on Thursday. The stock has a fifty day moving average of $1.93 and a 200 day moving average of $3.06. OpGen has a 52-week low of $1.61 and a 52-week high of $9.90.
OpGen (NASDAQ:OPGN – Get Free Report) last posted its quarterly earnings data on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. The firm had revenue of $0.03 million for the quarter.
Institutional Investors Weigh In On OpGen
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Recommended Stories
- Five stocks we like better than OpGen
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Stock Sentiment Analysis: How it Works
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- How to Use the MarketBeat Dividend Calculator
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.